Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12844321 | 0.84 | MAPT (0.40) | KDM4EPOLBMAPTHPGDPARP1 | |
| SCHEMBL25451172 | 0.80 | FABP6 (0.34) | KDM4EHPGDALDH1A1 | |
| SCHEMBL12775769 | 0.77 | KDM4E (0.36) | KDM4E | |
| SCHEMBL9797808 | 0.76 | PDK2 (0.40) | KDM4EPOLBMAPTHPGDPARP1 | |
| SCHEMBL8525361 | 0.73 | TYMS (0.32) | PARP1ALDH1A1TNKS2 | |
| SCHEMBL19678267 | 0.73 | ABL1 (0.36) | KDM4EPOLBMAPTHPGDALDH1A1 | |
| SCHEMBL13216944 | 0.73 | SCN10A (0.31) | — | |
| SCHEMBL5021590 | 0.72 | PDPK1 (0.33) | KDM4EHPGDALDH1A1 | |
| SCHEMBL12599032 | 0.70 | SMN1; SMN2 (0.33) | PARP1ALDH1A1TNKS2 | |
| SCHEMBL13377819 | 0.70 | PARP1 (0.30) | PARP1ALDH1A1TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059976-A1 | PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059976-A1 | PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KDM4E 1905/4885POLB 1446/4885MAPT 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.